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Since the discovery of the nervous system’s ability to produce steroid hormones,
numerous studies have demonstrated their importance in modulating neuronal
excitability. These central effects are mostly mediated through different ligand-gated
receptor systems such as GABAA and NMDA, as well as voltage-dependent Ca2+
or K+ channels. Because these targets are also implicated in transmission of sensory
information, it is not surprising that numerous studies have shown the analgesic
properties of neurosteroids in various pain models. Physiological (nociceptive) pain has
protective value for an organism by promoting survival in life-threatening conditions.
However, more prolonged pain that results from dysfunction of nerves (neuropathic
pain), and persists even after tissue injury has resolved, is one of the main reasons
that patients seek medical attention. This review will focus mostly on the analgesic
perspective of neurosteroids and their synthetic 5α and 5β analogs in nociceptive and
neuropathic pain conditions.
Keywords: neurosteroids, chronic pain, T-channel (CaV 3), T-channel calcium channel blockers, neurosteroid
analogs, analgesic (activity)

INTRODUCTION
Since the discovery of steroid hormone synthesis in the rat nervous system (Corpechot et al., 1981),
numerous studies have shown the pivotal role of steroid hormones in various neuronal functions,
such as cognition, memory, affective disorders, neuroprotection, and myelination (Schumacher
et al., 2012, 2014; Brinton, 2013; Giatti et al., 2015). These molecules are called neurosteroids,
because they are produced in the nervous system by neurons and/or glial cells (Baulieu and
Robel, 1990). Today, all steroid hormones that exert an effect on inhibitory and excitatory
neurotransmission, regardless of their mechanism(s) and source (whether they are synthetic or
endogenously produced), are considered neuroactive steroids (Paul and Purdy, 1992).
Neurosteroids are capable of modulating cell function on different levels. Conventionally,
their effects are attributable to specific nuclear hormone receptors (e.g., progesterone)
that regulate RNA expression. The onset of such effects is much slower, but the
consequential changes may be long lasting. On the other hand, neurosteroids also exert their
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humans and animal models, while estrogen can act both
as an analgesic and hyperalgesic (Aloisi, 2003; Ceccarelli
et al., 2003; Aloisi et al., 2004; Arendt-Nielsen et al., 2004;
Aloisi and Bonifazi, 2006). It is well known that fluctuations
of estrogen and progesterone during the estrous cycle can
influence pain perception and pain threshold (Frye et al.,
1992, 1993; Riley et al., 1998; Kuba and Quinones-Jenab,
2005). Furthermore, it seems that estrogen and progesterone
may regulate the antinociceptive conformation of mu and
kappa opioid receptor heterodimers (Chakrabarti et al.,
2010), which makes them immensely important in pain
regulation.
Several studies have confirmed the existence of particular
enzymes involved in steroidogenesis throughout the central
nervous system (CNS) and peripheral nervous system (PNS)
(for review Baulieu and Robel, 1990; Compagnone and Mellon,
2000; Mensah-Nyagan et al., 2009). These compounds are crucial
for plasticity of the nervous system (Patte-Mensah et al., 2006;
Melcangi et al., 2008); therefore, they also play a very important
role in pain perception and pain modulation. Interestingly,
extensive studies on the dorsal horn region of the spinal cord
have not been conducted. However, it is well known that the
dorsal horn of the spinal cord plays a pivotal role in the
transmission of painful stimuli from the peripheral nociceptors
to supraspinal structures. It is also well established that primary
afferent fibers coming from peripheral nociceptive neurons,
whose cell bodies lie in the dorsal root ganglia (DRG), form
synapses with the projection neurons of the dorsal horn of
the spinal cord. These neurons further convey information to
the brainstem, thalamic, and cortical structures (Millan, 1999,
2002) that are able to modulate nociceptive transmission via
several descending pathways at the level of the spinal cord.
Because modulation of pain perception occurs at the level of
dorsal horn neurons in the spinal cord, it is not surprising
that a particular set of enzymes, including a CYP450, involved
in steroidogenesis was identified (Patte-Mensah et al., 2004;
Mensah-Nyagan et al., 2008). An immunohistochemical study
by Patte-Mensah et al. (2003) has confirmed that the highest
density of these enzymes was detected in superficial layers of
laminae I and II, where the first synapses between the nociceptive
peripheral sensory neurons and projection neurons are located.
Furthermore, homogenates of the rat spinal cord were capable
of converting cholesterol into progesterone confirming that the
enzymes are indeed functional. Locally synthetized progesterone
in the spinal cord has also been shown to stimulate intrinsic
spinal anti-nociceptive system via kappa and delta opioid
receptors and promoting the increase of endorphins in situ
(Dawson-Basoa and Gintzler, 1997, 1998). Additionally, there
is evidence of direct inhibition of allopregnanolone synthesis
in the dorsal horn with substance P, a potent pronociceptive
neuropeptide (Patte-Mensah et al., 2005). This finding indicates
that the presence of neuroactive steroids at the level of the
dorsal horn could regulate GABA inhibitory tone, and that
the pronociceptive effect of substance P released from primary
afferents could be due to the reduction of GABAA receptor
activity by downregulating the production of 3α, 5α-THP
(allopregnanolone). These data strongly suggest that there

effects in the nervous system through modulation of various
receptor systems and ionic channels (Baulieu et al., 1999;
Mensah-Nyagan et al., 1999; Mellon and Griffin, 2002; Belelli
and Lambert, 2005). Some of them, such as GABAA and
NMDA receptors and/or voltage-dependent T-type Ca2+ or
voltage-dependent K+ channels, are heavily implicated in sensory
pathways responsible for mediating anesthesia and analgesia.
The present review focuses on the role of neurosteroids in pain
pathways, their potential as analgesics in different pain models,
and future therapeutic perspectives.

THE ROLE OF NEUROSTEROIDS IN PAIN
PATHWAYS
The International Association for the Study of Pain (IASP)
defines pain as “an unpleasant sensory and emotional experience
associated with actual or potential tissue damage, or described
in terms of such damage.” Although acute nociceptive pain has
protective value for an organism, promoting survival in lifethreatening conditions (Basbaum et al., 2009), prolonged pain
that persists even after tissue injury has resolved is one of the
main reasons that patients seek medical attention (Costigan et al.,
2009).
Some of the first studies with intravenously injected
cholesterol showed that steroid molecules could suppress painful
information and decrease arousal by exerting an anestheticlike state in mammals (Cashin and Moravek, 1927). In
this study, abdominal surgery on cats was performed after
intravenous (IV) administration of cholesterol, and animals
were fully recovered. The pregnane class of steroids has
become particularly important because of their allosteric
modulation of neuronal GABAA receptors. Brot et al. (1997)
showed that allopregnanolone mediates its anxiolytic effect
by stimulating chloride flux through the channel of GABAA
receptors via either binding sites different from the one
for benzodiazepines, or via sites allosterically linked to the
picrotoxin binding site. More recent studies have shown
that neurosteroids are influencing the kinetics of synaptic
GABAA -gated ion channels by prolonging the decay time of
phasic responses, and therefore enhancing neuronal inhibition
(Belelli and Lambert, 2005; Herd et al., 2007). Furthermore,
neurosteroids also exert their effects via extrasynaptic GABAA
receptors containing the δ-subunit, thus enabling tonic inhibition
(Lambert et al., 2001). This effect was confirmed in a
study of Stell et al. (2003) where tonic conductance was
significantly reduced in mice lacking the δ-subunit of GABAA
receptors, and was not influenced by 5α-pregnan-3α,21-diol20-one (3α,5α-tetrahydrodeoxycorticosterone,3α,5α-THDOC), a
potent stereoselective positive allosteric modulator of the GABAA
receptor. The anxiolytic and anesthetic effects of 3α,5α-THDOC
were attenuated in these mice (Mihalek et al., 1999). Altogether,
these findings could explain the ability of neurosteroids to induce
sedation and anesthesia in rodents.
Numerous clinical and animal studies have found that
sex hormones can differentially regulate pain perception.
For example, testosterone exerts analgesic effect in both
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FIGURE 1 | Neurosteroid synthesis in the spinal cord from cholesterol.

comparable to non-Tg mice (Wang et al., 2010). Furthermore, in
allopregnanolone treated 3xTgAD mice, a significant reduction
of β-amyloid production was noticeable (Chen et al., 2011).
Allopregnanolone increased dopamine release from nucleus
accumbens in freely moving rats (Rougé-Pont et al., 2002)
and improved motor performance by promoting neurogenesis
of tyrosine hydroxylase immunoreactive neurons is substantia
nigra (Adeosun et al., 2012) in the mouse model of Parkinson’s
disease.
Numerous studies have also shown that steroids modulate
pain sensitivity, either through intracellular/nuclear targets, or by
modulation of synaptic transmission, both directly and indirectly
via second-messenger systems. Potentiation of inhibitory GABAergic transmission in the pain pathway is one of the important
mechanisms to diminish pain transmission (Zeilhofer et al.,
2013). Predictably, analgesic potential of neuroactive steroids
that promote GABA-mediated transmission in different pain
paradigms is very well established.
Several other mechanisms are involved in analgesia induced
by neurosteroids. It has been shown that progesterone, applied
subcutaneously, successfully alleviated both mechanical and
thermal allodynia in the sciatic nerve injury model, by preventing
injury-induced increase of NR-1 subunit of NMDA receptors,
as well as expression of PKCγ (Coronel et al., 2011). This
reduction of PKCγ prevents the phosphorylation of NR1 subunit
of NMDA receptors, which is crucial for receptor facilitation

is an active process of neurosteroid synthesis in the dorsal
horn, particularly progesterone and allopregnanolone (two very
potent analgesic neurosteroids) by direct enzymatic conversion
(Figure 1).

ENDOGENOUS NEUROSTEROIDS AND
PAIN
Recent studies suggest that progesterone and its derivatives,
dihydroprogesterone (DHP) and 3α, 5α-tetrahydroprogesterone
(THP) or allopregnanolone, have a specific neuroprotective
action in the central and PNS (Guennoun et al., 2008, 2015;
Melcangi et al., 2014; Schumacher et al., 2014). For example,
these molecules are capable of exerting beneficial effects in
pathological conditions such as traumatic brain injury and
spinal cord injury by promoting myelination and preserving
white matter. In addition, endogenous neurosteroids show
positive therapeutic effect in conditions such as Alzheimer’s
and Parkinson’s disease (Irwin et al., 2014; Schumacher
et al., 2014). Allopregnanolone, in particular, has been shown
to promote neurogenesis by increasing neural progenitor
proliferation of subgranular zone of dentate gyrus in adult
3xTgAD mice. Furthermore, in the same mouse model of
Alzheimer’s disease, allopregnanolone reversed the conditioned
response/associative learning deficits of 3xTgAD mice to a level
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Dehydroepiandrosterone seems to possess another feature,
related to neuroprotection. A recent study of Lazaridis et al.
(2011) indicated that DHEA prevented neuronal apoptosis by
interacting with transmembrane tyrosine kinase receptor TrkA.
TrkA receptors are a known group of target receptors for the
nerve growth factor (NGF). Via these receptors, NGF prevents
cell apoptosis. Thus, the authors have discovered that, by binding
to TrkA, DHEA exerts an antiapoptotic effect in HEK-293 cells,
and reversal of apoptotic loss of TrkA positive sensory neurons in
DRG of NGF null mouse embryos.
On the other hand, NGF/TrkA signaling pathway has already
been implicated in pain transmission (Hirose et al., 2016). From
the developmental standpoint, NGF is necessary during fetal
period for normal growth of sensory nerve fibers belonging
to pain pathways. However, during the adulthood, an NGF
increase occurs during peripheral inflammation and nerve injury.
This increase of peripheral NGF leads to the sensitization of
surrounding nerves inducing pain, which is a protective response
to prevent further tissue injury. But, if the inflammation and
nociception persist, the protective value of increased NGF is lost
leading to central and peripheral sensitization of pain pathways,
and to the development of chronic pain states. This notion
has been confirmed in the study by Ashraf et al. (2016) where
an experimental compound has been utilized to antagonize
effects of NGF via blocking the TrkA receptors, and therefore
reducing pain and joint damage in rat models of inflammatory
arthritis. Interestingly, a synthetic analog of DHEA, named
BNN27, has been recently shown to interact with TrkA receptors
(Pediaditakis et al., 2016) on DRG neurons without exerting
pronociceptive behavior. This indicates a selective action against
neurodegeneration but not influencing the pain pathways.
Therefore, the rogue neurosteroid DHEA, and synthetic analogs,
could have a more pleiotropic role, by simultaneously interacting
with different receptor systems and hence, exerting different
effects, that could be both beneficial and detrimental, depending
on the activated pathways, age, and pathologies. Further studies
are needed to elucidate the mechanisms of these dichotomous
effects of DHEA in the pain pathway.
Progesterone’s metabolites, DHP and THP, have also been
proven to act as analgesics in various pain models. For example,
in the sciatic nerve crush injury model, progesterone and DHP
successfully alleviated thermal nociception. This is possibly
accomplished by restoring the thickness of the myelin and
reducing the density of the fibers, as well as normalizing the
function of Na+ /K+ -ATPase pump activity (Roglio et al., 2008).
In chemically induced neuropathies, such as streptozotocininduced diabetic neuropathy and chemotherapy-induced
neuropathy, progesterone, allopregnanolone, and 5α-DHP
have alleviated either thermal and/or mechanical nociception
(Leonelli et al., 2007; Meyer et al., 2010, 2011).
Pathirathna et al. (2005b) have shown that allopregnanolone
successfully alleviated mechanical and thermal hyperalgesia in
the neuropathic pain model of loose sciatic nerve ligation
in rats by modulating both T-type Ca2+ channels (Tchannels) and GABAA receptors. Specifically, allopregnanolone
was a more potent analgesic than its analogs, which

and contributes to the development of central sensitization.
Antiallodynic effect of progesterone was also achieved in the
spinal cord injury pain model (Coronel et al., 2014). The
authors have shown that application of progesterone significantly
reduced spinal expression of COX-2 and iNOS after spinal
cord injury, revealing an anti-inflammatory activity of this
endogenous neurosteroid that could contribute to its analgesic
properties. Furthermore, the existence of receptors in dorsal
horn neurons, sensitive to progesterone, supports the notion
of the importance of neurosteroid induced modulation of pain
processing (Labombarda et al., 2010). A particular type of
receptor, sigma-1 receptor, a chaperone residing in endoplasmic
reticulum, has recently been investigated as a potential target
for progesterone binding in the spinal cord (Maurice et al.,
2006; Monnet and Maurice, 2006; de la Puente et al., 2009).
Sigma-1 receptors chaperon proper folding of nascent proteins.
However, in certain conditions, such as binding of agonists,
they could translocate to the cell membrane and interact
with different G-protein coupled receptors and ionic channels.
Previous studies have confirmed the presence of sigma-1 receptor
in the dorsal horn neurons (de la Puente et al., 2009), as well
as on DRG (Mavlyutov et al., 2016) which implicates them in
the development of neuropathic pain and spinal sensitization
after nerve injury. It has also been shown that activation of
sigma-1 receptors leads to increased activity of PKC and PKA,
which in turn induces phosphorylation of NR1 subunit of NMDA
receptors, a process highly implicated in the development of
central sensitization (Kim et al., 2008). Ortíz-Rentería et al. (2018)
discovered that blocking sigma-1 receptors by progesterone leads
to a significant decrease of TRPV1-dependent pain produced by
capsaicin. Different authors have shown that treatment of sciatic
nerve constriction and orofacial pain models with progesterone
also successfully reduced mechanical and thermal allodynia
(Dableh and Henry, 2011; Kim et al., 2012).
Of particular interest is dehydroepiandrosterone (DHEA), one
of the first discovered neurosteroids (Baulieu et al., 1999). DHEA
is found to be converted from pregnenolone by cytochrome
P450c17 in the CNS. Although it can be found in human plasma,
in rodents, plasma levels are extremely low, most likely since
cytochrome P450c17 does not exist in rodent adrenals. However,
DHEA synthesis exists in the spinal cord (Kibaly et al., 2005), a
pivotal part of the sensory pathways, important for nociceptive
transmission. Therefore, the importance of DHEA in modulation
of pain perception should be considered. Kibaly et al. (2007)
have found that when injected either peripherally (subcutaneous)
or centrally (intrathecal), DHEA exerts pronociceptive effects by
reducing the pain thresholds to painful stimuli. However, the
repeated injections of DHEA exert a sustained analgesic effect.
This indicates that DHEA exerts its acute algogenic effects most
likely via either direct allosteric modulation of NMDA or P2X
receptors, or via sigma-1 receptors, which in turn enhances
phosphorylation of NR1 subunit of NMDA receptors (Yoon
et al., 2010), leading to increased sensitization of pain pathways.
On the other hand, delayed analgesic effect of DHEA could be
explained by its metabolism to androgens in the spinal cord, such
as testosterone, that exert analgesic effects (Kibaly et al., 2007).
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FIGURE 2 | Proposed mechanisms of analgesic effect of endogenous and synthetic neurosteroids.

systems, makes them an excellent alternative to conventional
therapeutic options for treating various pain states. On the
other hand, drugs that target so many receptor systems
often produce various adverse events in humans. Therefore,
creating a potent, but more selective, neuroactive steroid
would be a focus of future studies of these interesting
compounds.

only inhibited T-channels or potentiated GABAA -gated
currents.
Additionally, Ayoola et al. (2014) have found that local
paw injections of epipregnanolone, an endogenous 5β-reduced
neurosteroid without potentiating effects at GABAA receptors,
successfully alleviated mechanical and thermal sensitivity in both
wild-type mice and rats, but not in CaV 3.2 T-type calcium
channel knock-out mice. This suggests that the antinociceptive
effect of epipregnanolone is mediated largely by inhibition of
T-channels in peripheral nociceptors.
Taken together, these data strongly suggest that endogenously
produced neuroactive steroids are very potent analgesics in
different pain models, and that they exert their analgesic effects
via various receptor systems and ion channels, most notably
GABAA receptors and T-type calcium channels (Figure 2).
On one hand, their ability to evoke effects through different
receptor systems, either directly or through second-messenger
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the role of voltage-gated Ca2+ channels (VGCCs) has not
been explored as thoroughly. Based upon the membrane
potential that activates them, VGCCs can be divided into
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administration of ECN effectively reversed mechanical and
thermal hyperalgesia in painful diabetic neuropathy in morbidly
obese leptin-deficient ob/ob mice (Latham et al., 2009). In
addition, some studies have implicated GABAA receptors in
the dorsal horn of spinal cord as important targets for
treatment of painful diabetic neuropathy (Jolivalt et al., 2008).
These data strongly suggest that neurosteroids targeting either
T-type channels and/or GABAA receptors may be beneficial in
treatment of intractable pain associated with peripheral diabetic
neuropathy.
Recent behavioral and immunohistological studies have
confirmed the presence of both GABAA receptors and the
CaV 3.2 isoform of T-channels on the peripheral nociceptors
(Rose et al., 2013; Obradovic et al., 2015). CaV 3.2 isoform
of T-channels has also been found presynaptically in the
spinal cord where these channels support glutamate release
from the central endings of nociceptive sensory neurons (Jacus
et al., 2012). In addition, the CaV 3.1 isoform of T-channels
controls the opioidergic descending inhibition from the lowthreshold spiking GABAergic neurons in the periaqueductal
gray (PAG; Park et al., 2010). Some previous studies showed
that an increase of intracellular calcium in Purkinje cells
increases sensitivity to GABA (Llano et al., 1991). On the
other hand, intracellular calcium decreases the affinity of GABA
receptors in sensory neurons of the bullfrog (Inoue et al.,
1986). Perhaps, in the PNS, blocking the T-channels leads
to the decreased intracellular Ca2+ , which in turn leads to
the increased activity of GABAergic inhibition. Overall, these
data suggest that there is a strong interaction between the
GABAergic inhibitory system and T-type channels in both
central and peripheral components of the pain pathway.
However, exact mechanisms of this interaction remain to be
determined.
Previous work from our lab has also shown that synthetic
5β-reduced neurosteroids can successfully alleviate somatic
pain (Todorovic et al., 2004). The steroid structures tested
both in vitro and in vivo contain either 3-cyano and 17hydroxyl groups or 3-hydroxyl and 17-cyano groups. These
selective T-channel blockers have exerted significant and dosedependent analgesia when injected locally into the plantar
surface of the hind paw in healthy rats. Specifically, (3β,5β,17β)3-hydroxyandrostane-17-carbonitrile (3β-OH) was one of the
most effective synthetic 5β- reduced neurosteroids in alleviating
thermal nociception. Interestingly, the potency to block isolated
T-currents in DRG neurons in vitro corresponded well to their
potency to exert thermal antinociception in vivo. Furthermore,
3β-OH has been recently shown to possess hypnotic effect
and was able to induce loss of righting reflex in neonatal
rats without causing harmful effects to the brain of exposed
animals (Atluri et al., 2018). It is reasonable to assume that
both analgesic and hypnotic effects were likely exerted by
blocking low voltage activated T-channels, suggesting that
this novel synthetic neurosteroid with a specific and selective
mechanism of action could be used for preemptive analgesia
and anesthesia. However, further studies are needed to test
this notion, and to investigate the effects of other synthetic
neurosteroid analogs in both acute and chronic pain models.

two categories: high-voltage-activated (HVA) and low-voltageactivated T-type Ca2+ channels. Of interest for this review
are T-type Ca2+ channels that are important targets for many
analgesic neurosteroids. Since the discovery of the role of
these channels in neuronal excitability, and their presence
on peripheral sensory neurons whose cell bodies are located
in the DRG (Carbone and Lux, 1984), a growing interest
for studying these channels in pain transmission has arisen
(Todorovic et al., 2001; Bourinet et al., 2005; Jacus et al., 2012;
Rose et al., 2013). Therefore, synthetic analogs of neuroactive
steroids with affinity for T-channels have been synthetized
to investigate their role in both acute and chronic pain
models.
Among several synthetic 5α-analogs tested, our previous
work has shown that ECN, [(3β,5α,17β)-17-hydroxyestrane-3carbonitrile], a potent enantioselective blocker of T-channels
without potentiating effects at GABAA receptors (Todorovic
et al., 1998), induced potent analgesia when applied locally as an
intraplantar injection in healthy rats (Pathirathna et al., 2005a).
Furthermore, when combined with CDNC24, a GABAA selective
neurosteroid without analgesic effect per se, the antinociceptive
effect of ECN was greatly potentiated. This synergistic analgesia
was abolished with a GABAA -receptor antagonist biccuculine,
indicating that there is an interplay between GABAA receptors
and T-channels in peripheral nociceptors that helps them to
work in concert when alleviating acute pain (Pathirathna et al.,
2005a).
These two 5α-reduced analogs have been shown to alleviate
pain in chronic neuropathy as well. Our group has shown that
in a model of chronic constrictive injury (CCI) of the sciatic
nerve, local intraplantar injections of either ECN or CDNC24
more selectively alleviated thermal nociception in neuropathic
animals than in a sham group, as compared to allopregnanolone
or alphaxalone (Pathirathna et al., 2005b). This can be explained
by the fact that synthetic neurosteroids are more selective to
either GABAA and/or T-channels, while allopregnanolone and
alphaxalone have many other targets on which to exert their
antinociceptive effect.
The fact that CDNC24 exerted effect in injured but not in
healthy animals can be explained by the changes in expression
and/or conductance of GABAA receptors during injury. The
study of Xiao et al. (2002) has confirmed the increase in mRNA
levels for α5 subunit of GABAA receptors on the cell bodies
of peripheral sensory neurons, while Yang et al. (2004) have
shown the upregulation of α5 subunit of the GABAA receptor
in the spinal cord after nerve injury. It is noteworthy that both
alphaxalone and allopregnanolone may exert antinociceptive
effect through potentiating GABAA currents as well as inhibiting
T-currents. More importantly, after blocking the GABA-ergic
effect with biccuculine, a potent analgesia could still be observed,
indicating that a great portion of neurosteroid-induced analgesic
effect is related to the T-channel inhibition. As previously
mentioned, neuroactive steroids have various targets to prevent
mechanisms that trigger plasticity changes in the nervous
system. Perhaps a future strategy of preventing neuropathic
pain could be achieved by blocking T-channels heavily involved
in neuronal excitability. Furthermore, systemic intraperitoneal
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when applied as a part of a balanced anesthesia, thus potentially
reducing the necessity for other analgesic drugs, such as opioids
after surgery. By specifically targeting key ion channels that
contribute to the modulation of pain perception, synthetic
neurosteroids could in turn alleviate pain in patients, hopefully
with less adverse events than currently used therapies. Future
clinical trials are necessary to investigate their analgesic potential
and safety profile in the human population.

CONCLUSION
Endogenous neurosteroids are very potent molecules with
effects on many crucial processes in the nervous system. By
targeting several different receptor systems, they are able to
reduce maladaptive changes in the sensory nervous system,
which in turn could prevent the development of central
sensitization and chronic pain states. Perhaps, increasing the
production of endogenous neurosteroids, such as progesterone
and allopregnanolone, in the spinal cord and peripheral nerves
would be a future therapeutic option for treating various pain
states in humans. This strategy has already been employed in
several animal studies and has proven successful in neuropathic,
inflammatory, as well as in postoperative pain models (Aouad
et al., 2009; Giatti et al., 2009; Hernstadt et al., 2009; Mitro
et al., 2012; Xiong et al., 2017). By targeting specific translocator
protein-18 kDa (TSPO) and/or liver X receptors (LXR), it is
possible to increase neuronal steroidogenesis, thus preventing
systemic endocrine effects that could appear as a consequence of
systemic application of neurosteroids.
On the other hand, synthetic 5α- and 5β-reduced steroid
analogs have great potential in treating acute and chronic pain.
Since rigid steroid molecules can be sculpted to generate more
selective compounds towards GABAA receptors and T-channels,
they may be the most interesting in terms of further development
as novel pain therapies. An example would be 3β-OH, a synthetic
neurosteroid with hypnotic and analgesic properties, that could
be a promising new agent to reduce postsurgical hyperalgesia,
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